Compare YORW & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YORW | MRVI |
|---|---|---|
| Founded | 1816 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | YORW | MRVI |
|---|---|---|
| Price | $32.51 | $3.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.57 |
| AVG Volume (30 Days) | 84.7K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | $76,882,000.00 | ★ $192,435,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $7.69 | $9.04 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $29.68 | $1.67 |
| 52 Week High | $36.48 | $6.21 |
| Indicator | YORW | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 41.63 |
| Support Level | $33.11 | $3.44 |
| Resistance Level | $32.99 | $3.59 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 4.21 | 6.71 |
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.